基质金属蛋白酶7（MMP7）和硫酸乙酰肝素糖蛋白2（HSPG2）在胰腺癌中的表达及临床意义

陈金凤; 陆小柳; 张晓韵; 唐曦平

doi:10.3969/j.issn.1001-5256.2023.09.020

基质金属蛋白酶7（MMP7）和硫酸乙酰肝素糖蛋白2（HSPG2）在胰腺癌中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2023.09.020

1.
广西医科大学肿瘤医学院，南宁 530021
2.
广西医科大学附属肿瘤医院内镜中心，南宁 530021

基金项目:

广西自然科学基金 (2020GXNSFAA297062);

广西医疗卫生适宜技术开发与推广应用项目 (S2020103);

广西壮族自治区中医药管理局科研项目 (GZZC2020235)

伦理学声明：本研究方案经由广西医科大学附属肿瘤医院伦理委员会审批，批号：LW2023010。

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：陈金凤负责课题设计，资料分析，撰写论文；陆小柳、张晓韵参与收集数据；唐曦平负责提供经费支持，设计研究思路，指导撰写文章并最后定稿。

详细信息

通信作者:
唐曦平， tangxiping108@hotmail.com （ORCID： 0000－0003－0156－9429）

计量
- 文章访问数: 226
- HTML全文浏览量: 77
- PDF下载量: 22
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-15
- 录用日期: 2023-02-06
- 出版日期: 2023-09-19

Expression and clinical significance of matrix metalloproteinase 7 and heparan sulfate proteoglycan 2 in pancreatic cancer

1.
School of Medical Oncology，Guangxi Medical University，Nanning 530021，China
2.
Endoscopy Center，Guangxi Medical University Cancer Hospital，Nanning 530021，China

Research funding:

Guangxi Natural Science Foundation (2020GXNSFAA297062);

Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project (S2020103);

Scientific Research Project of Guangxi Administration of Traditional Chinese Medicine (GZZC2020235)

More Information

Corresponding author: TANG Xiping， tangxiping108@hotmail.com （ORCID： 0000－0003－0156－9429）

摘要

摘要: 目的探讨基质金属蛋白酶7（MMP7）和硫酸乙酰肝素糖蛋白2（HSPG2）在胰腺癌患者中的表达及临床意义。方法选取2018年1月—2020年12月广西医科大学附属肿瘤医院收治的胰腺癌患者30例，收集胰腺癌组织标本及其血清样本，同时收集癌旁正常组织以及30例健康志愿者血清样本作为对照。采用免疫组化方法检测胰腺癌组织及癌旁正常组织中MMP7和HSPG2蛋白表达；采用酶联免疫吸附法检测胰腺癌患者和健康对照者血清样本中MMP7和HSPG2的表达水平；收集患者临床资料并分析MMP7和HSPG2表达与临床病理特征、生存预后的关系。计量资料两组间比较采用成组t检验。计数资料组间比较采用χ²检验或Fisher确切概率法。MMP7与HSPG2表达的关系采用Spearman相关分析。采用Kaplan－Meier法绘制生存曲线，生存情况比较采用Log－rank检验。结果免疫组化结果显示，胰腺癌组织中MMP7和HSPG2蛋白阳性表达均高于癌旁组织，差异均有统计学意义（χ²值分别为31.093、35.623，P值<0.05）。胰腺癌患者血清中MMP7、HSPG2水平均显著高于健康对照组（t值分别为20.174、32.600，P值<0.05）。MMP7和HSPG2表达均与肿瘤直径、TNM分期有关（P值<0.05）。Spearman相关性分析显示，HSPG2与MMP7之间的表达呈正相关（r=0.539，P=0.002）。MMP7和HSPG2蛋白阳性表达患者总生存率明显低于阴性对照患者（χ²值分别为4.084、12.554，P值均<0.05）。结论 MMP7和HSPG2在胰腺癌组织和血清中呈阳性表达，且与肿瘤的直径、TNM分期有关，两者可能在胰腺癌的发生发展中存在某种关联，有望成为胰腺癌诊断和判断预后的潜在标志物。
- 胰腺肿瘤 /
- 基质金属蛋白酶7 /
- 类肝素硫酸蛋白聚糖类
Abstract: Objective To investigate the expression and clinical significance of matrix metalloproteinase 7 （MMP7） and heparan sulfate proteoglycan 2 （HSPG2） in patients with pancreatic cancer. Methods Pancreatic cancer tissue samples， normal adjacent tissue samples， and serum samples were collected from 30 patients who were admitted to Guangxi Medical University Cancer Hospital from January 2018 to December 2020， and serum samples were collected from 30 healthy volunteers as controls. Immunohistochemistry was used to measure the protein expression levels of MMP7 and HSPG2 in pancreatic cancer tissue samples and normal adjacent tissue samples； ELISA was used to measure the expression levels of MMP7 and HSPG2 in the serum samples of the pancreatic cancer patients and the healthy controls； related clinical data were collected to analyze the association of the expression of MMP7 and HSPG2 with clinicopathological features， survival， and prognosis. The independent－samples t test was used for comparison of continuous data between two groups， and the chi－square test or the Fisher’s exact test was used for comparison of categorical data between two groups； the Spearman correlation analysis was used to investigate the correlation between MMP7 and HSPG2； the Kaplan－Meier method was used to plot survival curves， and the Log－rank test was used for survival analysis. Results Immunohistochemistry showed that the protein expression levels of MMP7 and HSPG2 in pancreatic cancer tissue were significantly higher than those in adjacent tissue （χ²=31.093 and 35.623， both P<0.05）. The patients with pancreatic cancer had significantly higher serum levels of MMP7 and HSPG2 than the healthy controls （t=20.174 and 32.600， both P<0.05）. The expression of MMP7 and HSPG2 was associated with tumor diameter and TNM stage （both P<0.05）. The Spearman correlation analysis showed a positive correlation between HSPG2 and MMP7 （r=0.539， P=0.002）. The patients with positive protein expression of MMP7 and HSPG2 had a significantly lower overall survival rate than those with negative expression （χ²=4.084 and 12.554， both P<0.05）. Conclusion MMP7 and HSPG2 are highly expressed in pancreatic cancer tissue and serum and are associated with tumor diameter and TNM stage. They may also be associated with the development and progression of pancreatic cancer， and therefore， they are expected to become potential markers for the diagnosis and prognostic evaluation of pancreatic cancer.
- Pancreatic Neoplasms /
- Matrix Metalloproteinase 7 /
- Heparan Sulfate Proteoglycans

HTML全文

图 1 胰腺癌组织及癌旁正常组织中MMP7、HSPG2的表达情况（免疫组化，×200）

注： a，癌旁正常组织HSPG2阴性；b，癌组织HSPG2阳性表达；c，癌旁正常组织MMP7阴性；d，癌组织MMP7阳性表达。

Figure 1. Expression of MMP7 and HSPG2 in pancreatic cancer tissues and in adjacent cancer normal tissues （immunohistochemistry， ×200）

下载: 全尺寸图片幻灯片

图 2 MMP7、HSPG2蛋白表达与胰腺癌患者生存时间的关系

注： a，HSPG2表达与胰腺癌患者预后关系的Kaplan－Meier生存曲线；b，MMP7表达与胰腺癌患者预后关系的Kaplan－Meier生存曲线。

Figure 2. Relationship between MMP7 and HSPG2 protein expression and survival time of pancreatic cancer patients

下载: 全尺寸图片幻灯片

表 1 MMP7和HSPG2在胰腺癌及癌旁正常组织中的阳性表达

Table 1. Positive expression of MMP7 and HSPG2 in pancreatic cancer and normal adjacent tissues

组别	例数	HSPG2阳性（例）	MMP7阳性（例）
胰腺癌组织	30	22	25
癌旁正常组织	30	1	2
χ²值		31.093	35.623
P值		<0.001	<0.001

下载: 导出CSV

表 2 HSPG2和MMP7表达与胰腺癌临床病理特征的关系

Table 2. Relationship between HSPG2 and MMP7 expression and clinicopathological features of pancreatic cancer

项目	HSPG2		P值	MMP7		P值
项目	阴性（n=8）	阳性（n=22）	P值	阴性（n=5）	阳性（n=25）	P值
性别（例）			>0.05			>0.05
女	3	11		2	12
男	5	11		3	13
肿瘤直径（例）			0.003			0.019
>4 cm	6	3		4	5
≤4 cm	2	19		1	20
肿瘤部位（例）			>0.05			>0.05
头颈部	5	14		3	16
胰体尾部	3	8		2	9
分化程度（例）			>0.05			>0.05
高	3	2		1	4
中+低	5	20		4	21
TNM分期（例）			0.039			0.031
Ⅰ～Ⅱ	1	13		0	14
Ⅲ～Ⅳ	7	9		5	11
有无转移（例）			>0.05			>0.05
是	7	15		4	18
否	1	7		1	7

下载: 导出CSV

表 3 HSPG2和MMP7表达的相关性分析

Table 3. Correlation analysis of the expression of both HSPG2 and MMP7

HSPG2	MMP7		r值	P值
HSPG2	阳性	阴性	r值	P值
阳性	21	1	0.539	0.002
阴性	4	4	0.539	0.002

下载: 导出CSV

表 4 各组间血清中MMP7、HSPG2的表达水平比较

Table 4. Comparison of expression levels of MMP7 and HSPG2 in serum between groups

组别	例数	MMP7（ng/mL）	HSPG2（ng/mL）
胰腺癌组	30	4.05±0.51	267.53±33.83
健康对照组	30	1.55±0.45	59.45±8.80
t值		20.174	32.600
P值		<0.001	<0.001

下载: 导出CSV

参考文献(17)

[1]	SZYMOŃSKI K, MILIAN－CIESIELSKA K, LIPIEC E, et al. Current pathology model of pancreatic cancer[J]. Cancers(Basel), 2022, 14( 9): 2321. DOI: 10.3390/cancers14092321.
[2]	ANDERSSON R, HAGLUND C, SEPPÄNEN H, et al. Pancreatic cancer－the past, the present, and the future[J]. Scand J Gastroenterol, 2022, 57( 10): 1169－ 1177. DOI: 10.1080/00365521.2022.2067786.
[3]	GRINDEL BJ, MARTINEZ JR, TELLMAN TV, et al. Matrilysin/MMP－7 cleavage of perlecan/HSPG2 complexed with semaphorin 3A supports FAK－mediated stromal invasion by prostate cancer cells[J]. Sci Rep, 2018, 8( 1): 7262. DOI: 10.1038/s41598－018－25435－3.
[4]	MENG N, LI Y, JIANG P, et al. A comprehensive pan－cancer analysis of the tumorigenic role of matrix metallopeptidase 7(MMP7) across human cancers[J]. Front Oncol, 2022, 12: 916907. DOI: 10.3389/fonc.2022.916907.
[5]	CRUZ LA, TELLMAN TV, FARACH－CARSON MC. Flipping the molecular switch: Influence of perlecan and its modifiers in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1245: 133－ 146. DOI: 10.1007/978－3－030－40146－7_6.
[6]	QIN W, YANG JY, CHEN TW, et al. Expression and significance of L1 cell adhesion molecule and transforming growth factor－β1 in pancreatic cancer tissue[J]. J Clin Hepatol, 2021, 37( 6): 1404－ 1408. DOI: 10.3969/j.issn.1001－5256.2021.06.035. 秦雯, 杨建宇, 陈泰文, 等. 胰腺癌组织中L1细胞黏附分子和转化生长因子β1的表达及意义[J]. 临床肝胆病杂志, 2021, 37( 6): 1404－ 1408. DOI: 10.3969/j.issn.1001－5256.2021.06.035.
[7]	NIKŠIĆ M, MATZ M, VALKOV M, et al. World－wide trends in net survival from pancreatic cancer by morphological sub－type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000－2014(CONCORD－3)[J]. Cancer Epidemiol, 2022, 80: 102196. DOI: 10.1016/j.canep.2022.102196.
[8]	MANRAI M, TILAK T, DAWRA S, et al. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities[J]. World J Gastroenterol, 2021, 27( 39): 6572－ 6589. DOI: 10.3748/wjg.v27.i39.6572.
[9]	MAO N, HUANG ZJ, LIN ZT, et al. Current status of the application of translational medicine in the early diagnosis of pancreatic cancer[J]. Chin J Dig Surg, 2021, 20( 4): 466－ 470. DOI: 10.3760/cma.j.cn115610－20210117－00029. 毛宁, 黄子健, 林志涛, 等. 转化医学在胰腺癌早期诊断中的应用现状[J]. 中华消化外科杂志, 2021, 20( 4): 466－ 470. DOI: 10.3760/cma.j.cn115610－20210117－00029.
[10]	PEZESHKIAN Z, NOBILI S, PEYRAVIAN N, et al. Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer[J]. Cancers(Basel), 2021, 13( 24): 6226. DOI: 10.3390/cancers13246226.
[11]	WATTANAWONGDON W, BARTPHO TS, TONGTAWEE T. Expression of matrix metalloproteinase－7 predicts poor prognosis in gastric cancer[J]. Biomed Res Int, 2022, 2022: 2300979. DOI: 10.1155/2022/2300979.
[12]	YUAN JQ, ZHANG KJ, WANG SM, et al. YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple－negative breast cancer[J]. Gland Surg, 2021, 10( 9): 2799－ 2814. DOI: 10.21037/gs－21－612.
[13]	TELLMAN TV, CRUZ LA, GRINDEL BJ, et al. Cleavage of the perlecan－semaphorin 3A－plexin A1－neuropilin－1(PSPN) complex by matrix metalloproteinase 7/matrilysin triggers prostate cancer cell dyscohesion and migration[J]. Int J Mol Sci, 2021, 22( 6): 3218. DOI: 10.3390/ijms22063218.
[14]	MARTINEZ JR, DHAWAN A, FARACH－CARSON MC. Modular proteoglycan perlecan/HSPG2: Mutations, phenotypes, and functions[J]. Genes(Basel), 2018, 9( 11): 556. DOI: 10.3390/genes9110556.
[15]	KAZANSKAYA GM, TSIDULKO AY, VOLKOV AM, et al. Heparan sulfate accumulation and perlecan/HSPG2 up－regulation in tumour tissue predict low relapse－free survival for patients with glioblastoma[J]. Histochem Cell Biol, 2018, 149( 3): 235－ 244. DOI: 10.1007/s00418－018－1631－7.
[16]	LORD MS, JUNG M, CHENG B, et al. Transcriptional complexity of the HSPG2 gene in the human mast cell line, HMC－1[J]. Matrix Biol, 2014, 35: 123－ 131. DOI: 10.1016/j.matbio.2013.12.005.
[17]	FARACH－CARSON MC, WARREN CR, HARRINGTON DA, et al. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders[J]. Matrix Biol, 2014, 34: 64－ 79. DOI: 10.1016/j.matbio.2013.08.004.